证券代码：002022 证券简称：科华生物 公告编号：2025-022 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 估值提升计划 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、触及情形及审议程序 （一）触及情形 根据《上市公司监管指引第10号——市值管理》，股票连续12个月每个交易 日收盘价均低于其最近一个会计年度经审计的每股归属于公司普通股股东的净 资产（以下简称"长期破净"）的上市公司，应当制定上市公司估值提升计划， 并经董事会审议后披露。 自2024年4月1日至2025年3月31日，上海科华生物工程股份有限公司（以下 简称"公司"）股票连续12个月每个交易日的收盘价均低于2023年经审计每股净 资产8.11元，属于应当制定估值提升计划的情形。 （二）审议程序 公司于2025年4月24日召开第十届董事会第十二次会议，以9票同意、0票反 对、0票弃权审议通过了《关于<估值提升计划>的议案》，同意公司实施本次估值 提升计划。该议案无需提交股东大会审议。 （一）聚焦主业，推动高质量发展 公司深耕体外诊断行业40余年，凭借自身多 ...

Financial Performance - The company's operating revenue for 2024 was ¥1,759,197,330.48, a decrease of 27.55% compared to ¥2,428,075,213.95 in 2023[19]. - The net profit attributable to shareholders for 2024 was -¥640,601,876.82, representing a decline of 173.74% from -¥234,014,886.40 in 2023[19]. - The cash flow from operating activities improved by 89.45%, reaching -¥50,115,999.67 in 2024 compared to -¥474,894,786.47 in 2023[19]. - The basic earnings per share for 2024 was -¥1.2687, a decrease of 178.84% from -¥0.4550 in 2023[19]. - The total assets at the end of 2024 were ¥5,236,128,052.84, down 23.09% from ¥6,807,739,866.34 at the end of 2023[19]. - The company's net assets attributable to shareholders decreased by 19.71%, from ¥4,172,116,724.60 in 2023 to ¥3,349,826,403.95 in 2024[20]. - The company's total revenue for 2024 was approximately ¥1.76 billion, a decrease of 27.55% compared to ¥2.43 billion in 2023[60]. - Sales revenue from self-produced products dropped by 38.90% to ¥865.82 million, accounting for 49.22% of total revenue[60]. - Domestic revenue fell by 34.47% to ¥1.36 billion, representing 77.14% of total revenue, while international revenue increased by 12.62% to ¥402.08 million, making up 22.86% of total revenue[60]. Market Overview - The global IVD market size is projected to reach $109.2 billion in 2024, with a compound annual growth rate (CAGR) of approximately 4.3% expected until 2029[30]. - The Chinese IVD market size grew from ¥43 billion in 2016 to ¥118.5 billion in 2023, with a CAGR of 15.58%[32]. - The Chinese in vitro diagnostic market is projected to reach RMB 190 billion by 2029, with a compound annual growth rate (CAGR) of 8.2% from 2023[33]. - The global veterinary in vitro diagnostic market was valued at RMB 39.4 billion in 2020, growing by 19.8%, and is expected to reach RMB 59.4 billion by 2025[35]. - The Chinese pet disease diagnosis market is expected to grow from RMB 8.3 billion in 2020 to RMB 18.2 billion by 2025, with a CAGR of 17.1%[35]. Risk Management - The company has a comprehensive risk assessment in its future outlook, highlighting potential market and macroeconomic uncertainties[4]. - The company emphasizes the importance of risk awareness for investors regarding forward-looking statements[4]. - The company has established a risk management system for foreign exchange hedging to mitigate market, liquidity, credit, operational, and legal risks[91]. - The company’s hedging activities are based on actual foreign currency cash flows to avoid exceeding the total amount of international business foreign exchange receipts and payments[91]. Research and Development - The company has established several important R&D centers and has received multiple honors, including being recognized as a national high-tech enterprise[41]. - The company continues to invest in R&D to enrich its product line and maintain its leadership in the in vitro diagnostic market[49]. - The company aims to enhance its product offerings by integrating instruments and reagents, providing flexible product combinations for customers[51]. - The company is committed to enhancing R&D capabilities and adjusting marketing strategies to maintain competitive advantage in response to intensified industry competition[109]. - The company has established a regulatory affairs department to ensure timely product registration in domestic and international markets, reducing registration risks[110]. Corporate Governance - The company has implemented a "Quality and Return Improvement" action plan to enhance operational quality and shareholder returns[113]. - The governance structure includes a board of directors and specialized committees to ensure compliance and protect shareholder rights[115]. - The company emphasizes timely information disclosure and investor communication, utilizing various channels to ensure shareholders and bondholders are well-informed[164]. - The company has established a robust governance structure to protect shareholder rights and has revised multiple internal regulations to enhance compliance and internal control effectiveness[163]. Strategic Initiatives - The company plans to enhance its international market share by providing comprehensive solutions in biochemistry, immunology, molecular diagnostics, and POCT products[56]. - The company aims to diversify its overseas markets and optimize its supply chain in response to international uncertainties[107]. - The company plans to leverage its capital market advantages for mergers and acquisitions to strengthen its core IVD industry ecosystem[108]. - The company is committed to complying with industry regulations and enhancing its compliance management system to mitigate risks from regulatory changes[108]. Employee Management - The company emphasizes a fair and competitive compensation policy to attract and retain talent, aligning employee contributions with their value[147]. - The company has a training system in place to enhance employee skills and support strategic goals, including various training programs for different employee levels[148]. - The total number of employees at the end of the reporting period is 2,033, with 846 in the parent company and 1,187 in major subsidiaries[146]. Environmental Responsibility - The company emphasizes sustainable development and social responsibility, focusing on balanced performance across economic, environmental, and social dimensions[162]. - No major environmental violations were reported, and the company has taken measures to reduce carbon emissions[162]. Financial Management - The company has independent financial management, with a dedicated finance department and a standardized financial accounting system, ensuring independent financial decision-making[120]. - The company has not engaged in speculative derivative investments during the reporting period[92]. - The company has no significant litigation or arbitration matters pending as of the reporting period, with a total of ¥5,749.47 million involved in ongoing cases[179].

上海科华生物工程股份有限公司（以下简称"公司"）于2025年4月24日召开第 十届董事会第十二次会议，审议通过了《关于召开公司2024年度股东大会的议案》， 现将本次股东大会的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024年度股东大会 2、股东大会的召集人：公司董事会 3、本次股东大会会议的召开符合《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司股东大会规则》、《深圳证券交易所股票上市规则》等有关法 律、行政法规、部门规章、规范性文件以及《上海科华生物工程股份有限公司章程》 的规定。 4、会议召开的日期和时间： 证券代码：002022 证券简称：科华生物 公告编号：2025-026 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 关于召开2024年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 （1）现场会议时间：2025年5月19日（星期一）下午14:30 （2）网络投票时间：2025年5月19日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为2025年5月19 日 ...

证券代码：002022 证券简称：科华生物 公告编号：2025-017 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 《 2024 年 度 监 事 会 工 作 报 告 》 同 日 披 露 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）。 本议案尚需提交公司2024年度股东大会审议。 表决结果：同意3票，反对0票，弃权0票。 （二）审议通过《关于<2024年度财务决算报告>的议案》 第十届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第十届监事会第八次 会议（以下简称"本次会议"或"会议"）通知于2025年4月14日以邮件方式送达 各位监事，会议于2025年4月24日在上海市徐汇区钦州北路1189号公司会议室以 现场方式召开。本次会议应出席监事3人，实际出席监事3人，本次会议由监事会 主席易超先生主持。会议的召开符合《中华人民共和国公司法》（以下简称"《公 司法》"）、《上海科华生物工程股份有限公司章程》和 ...

| 证券代码:002022 | | --- | | 债券代码:128124 | 证券代码：002022 证券简称：科华生物 公告编号：2025-016 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 第十届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第十届董事会第十二 次会议（以下简称"本次会议"或"会议"）通知于2025年4月14日以邮件方式送 达全体董事、监事及高级管理人员，会议于2025年4月24日在上海市徐汇区钦州 北路1189号公司会议室以现场结合通讯会议方式召开。本次会议应参会董事9人， 实际参会董事9人（包含3名独立董事），公司监事及高级管理人员列席了本次会 议。本次会议由公司董事长李明先生主持。会议的召开符合《中华人民共和国公 司法》（以下简称"《公司法》"）、《上海科华生物工程股份有限公司章程》（以下 简称"《公司章程》"）和《上海科华生物工程股份有限公司董事会议事规则》的 有关规定。 二、董事会会议审议情况 （一 ...

| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2025-019 | 上海科华生物工程股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 1、董事会审议情况 公司于 2025 年 4 月 24 日召开第十届监事会第八次会议，以 3 票同意，0 票 反对，0 票弃权审议通过了《关于 2024 年度利润分配预案的议案》。经审议，监 事会认为：公司 2024 年度利润分配预案符合《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司监管指引第 3 号——上市公司现金分红》（以下简称"《现金分红指引》"）等法 律法规及公司利润分配政策，符合公司实际情况和发展需要，不存在损害公司股 东特别是中小股东利益的情形。因此，我们同意公司 2024 年度利润分配预案。 3、本议案尚需提交公司 2024 年度股东大会审议。 二、2024 年 ...

| 证券代码：002022 | 证券简称：科华生物 | | --- | --- | | 债券代码：128124 | 公告编号：2025-015 债券简称：科华转债 | 关于产品获得医疗器械注册证的公告 上海科华生物工程股份有限公司 特此公告。 上海科华生物工程股份有限公司董事会 2025年4月23日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，上海科华生物工程股份有限公司（以下简称"公司"）全资子公司科 华（西安）生物工程有限公司收到陕西省药品监督管理局颁发的医疗器械注册证。 具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期 | 适用范围/预期用途 | | --- | --- | --- | --- | --- | | 1 | 全自动化学 发光免疫分析仪 | 陕械注准 20252220088 | | 该产品采用基于吖啶酯的直接 | | | | | 2025年04月14日 | 化学发光法，与配套的检测试剂 | | | | | 至 | 共同使用，在临床上用于对来源 | | | | | 2030年04月13日 | 于人体的血清、血浆 ...

Group 1 - The core viewpoint of the news is that Kehua Bio's stock has shown a slight increase, with a closing price of 5.38 yuan and a market capitalization of 2.767 billion yuan, despite a significant decline in revenue and net profit in the latest financial report [1] - On April 10, 2024, Kehua Bio experienced a net inflow of 936,200 yuan in main funds, indicating a positive trend in fund flow over the past five days, totaling an inflow of 823,600 yuan [1] - Kehua Bio specializes in the research, production, and sales of in vitro diagnostic reagents and medical testing instruments, with its products primarily used in clinical hospital testing and blood donation screening [1] Group 2 - The latest financial results for Kehua Bio show a revenue of 1.35 billion yuan for the third quarter of 2024, representing a year-on-year decrease of 29.09%, and a net loss of approximately 122.14 million yuan, a decline of 512.11% compared to the previous year [1] - The company's gross profit margin stands at 40.04%, indicating its ability to maintain profitability despite the decline in revenue [1] - In comparison to industry averages, Kehua Bio's price-to-earnings (PE) ratio is significantly lower at -8.23, while the industry average PE is 46.15, highlighting the company's underperformance relative to its peers [2]

Core Viewpoint - The company has signed an investment cooperation agreement with the Xi'an Economic and Technological Development Zone Management Committee to establish a medical equipment and testing reagent production base and a medical industry incubation innovation center, covering approximately 90 acres of land [3][5]. Group 1: Agreement Overview - The agreement was signed on April 8, 2025, and is structured in two phases: the first phase involves a production base for medical equipment and testing reagents on approximately 50 acres, while the second phase will focus on a medical industry incubation center on about 40 acres [3][5]. - The first phase aims to produce 72 million testing reagents and 3,000 sets of testing equipment annually upon completion [5]. Group 2: Counterparty Information - The counterparty, Xi'an Economic and Technological Development Zone Management Committee, is a national-level economic and technological development zone established in 1993, focusing on advanced manufacturing and export-oriented economic development [4]. Group 3: Agreement Details - The company will establish an independent legal entity in the Xi'an Economic and Technological Development Zone to manage the project, ensuring compliance with local planning and legal requirements [6]. - The management committee will provide land and support for project approvals, environmental protection, and safety [6]. Group 4: Impact on the Company - The agreement is a framework and does not affect the company's operational independence; the financial impact will depend on the execution of specific project agreements in the future [7].

| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2025-014 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、本次签署的投资合作协议属于双方基于合作意愿而达成的框架性、意向 性约定，后续具体的合作事宜尚需进一步协商确定，上海科华生物工程股份有限 公司（以下简称"科华生物"或"公司"）将根据后续进展情况，按照相关法律 法规及《上海科华生物工程股份有限公司章程》（以下简称"《公司章程》"）的有 关规定，及时履行相应的审批程序和信息披露义务。敬请广大投资者谨慎决策， 注意投资风险； 1、名称：西安经济技术开发区管委会 2、本协议为后续双方推进具体项目合作的基础，对公司本年度及后续年度 的财务状况和经营成果的影响尚存在不确定性； 3、截至本公告披露日，公司最近三年未披露过框架协议。 一、协议签署概况 2025年4月8日，公司与西安经济技术开发区管委会签署了《医疗设备及检测 试剂生产基地和医疗产业孵化创新中心项目投资合作协议》。公司拟在西安经 ...